BIO · XBRL financial data

Bio-Rad Laboratories financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (BIO's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	632	681*	611	638	650	667*	585	652	653	693*	592	651
Cost of goods and services sold	296	315*	285	283	294	326*	279	306	310	348*	283	305
Gross profit	336	366	326	355	356	342	306	345	343	345*	309	346
Research and development	44	64*	66	59	91	80*	74	61	71	70*	63	61
Selling, general and administrative	201	207*	215	195	200	204*	209	208	207	221*	212	212
Operating income (loss)	91	95*	45	101	64	58*	24	77	65	(119)*	34	73
Interest expense	12	12*	12	12	12	12*	12	13	12	12*	12	12
Other income (expense)	20	19*	35	18	18	20*	37	16	8	29*	24	23
Income tax expense (benefit)	31	79*	107	(621)	208	(193)*	19	96	(89)	209*	(163)	171
Net income (loss)	106	350	384	(2,165)	653	(716)	64	318	(342)	720*	(527)	371
Earnings per share, basic USD per share	3.65	12.15	13.46	(76.26)	23.37	(25.57)	2.29	11.67	(12.70)	26.69*	(19.55)	13.89
Earnings per share, diluted USD per share	3.64	12.14	13.45	(76.26)	23.34	(25.57)	2.29	11.67	(12.70)	26.64*	(19.55)	13.85
Weighted average shares, basic millions of shares	29	29*	29	28	28	28*	28	27	27	27*	27	27
Weighted average shares, diluted millions of shares	29	29*	29	28	28	28*	28	27	27	27*	27	27

Fiscal quarters (BIO's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	458	404	433	407	410	488	521	369	396	530	507	517
Short-term investments	1,301	1,203	1,212	1,209	1,212	1,176	1,139	1,005	1,023	1,011	1,058	1,102
Accounts receivable	457	489	445	446	462	453	425	470	465	461	426	442
Inventory	776	781	783	804	804	760	790	799	783	741	771	781
Total current assets	3,147	3,048	3,061	3,056	3,056	3,030	3,037	2,811	2,842	2,906	2,942	3,021
Property and equipment, net	—	529	—	—	—	528	—	—	—	540	—	—
Right-of-use asset	200	195	189	181	174	161	153	190	180	170	162	154
Goodwill	407	414	413	412	415	411	415	582	579	580	577	574
Total assets	11,896	12,299	12,610	9,688	10,603	9,364	9,527	10,214	9,696	10,577	9,790	10,252
Accounts payable	112	145	103	127	122	122	138	139	129	129	133	144
Total current liabilities	558	523	466	487	498	468	507	549	522	517	917	961
Long-term debt	1,199	1,199	1,199	1,200	1,200	1,200	1,201	1,201	1,201	1,202	803	803
Lease liability, non-current	167	165	160	151	144	131	126	165	156	146	139	133
Total liabilities	3,480	3,558	3,559	2,910	3,116	2,795	2,848	3,085	2,960	3,123	2,939	3,078
Retained earnings	8,911	9,261	9,645	7,479	8,132	7,416	7,480	7,798	7,456	8,176	7,649	8,021
Total stockholders' equity	8,416	8,741	9,051	6,779	7,488	6,569	6,679	7,129	6,737	7,454	6,851	7,174
Total liabilities and equity	11,896	12,299	12,610	9,688	10,603	9,364	9,527	10,214	9,696	10,577	9,790	10,252

Fiscal quarters (BIO's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	106	350	384	(2,165)	653	(716)	64	318	(342)	720*	(527)	371
Stock-based compensation	16*	16*	15	15*	16*	16*	15	12*	15*	16*	15	15*
Depreciation and amortization	—	year only	—	—	—	year only	—	—	—	year only	—	—
Net cash from operating activities	98*	81*	70	98*	164*	124*	130	117*	121*	165*	108	99*
Purchases of property and equipment	44*	42*	40	42*	40*	43*	34	46*	32*	46*	30	32*
Net cash from investing activities	(10)*	72*	(43)	(31)*	(56)*	(31)*	3	(115)*	(43)*	(34)*	(93)	(67)*
Proceeds from issuing common stock	(5)	—	6	5*	5*	—	4	4*	3*	—	3	4*
Share repurchases	21*	200*	5	101*	98*	0*	102	140*	53*	0*	48	32*
Repayments of long-term debt	0*	0*	0	0*	0*	0*	0	0*	0*	0*	0	0*
Net cash from financing activities	(27)*	(201)*	0	(97)*	(96)*	(26)*	(98)	(136)*	(53)*	3*	(44)	(28)*
Net change in cash	68*	(54)*	29	(26)*	4*	78*	33	(151)*	27*	134*	(23)	10*

SIC 3826 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3826 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Bio-Rad Laboratories	517	651	99*	not reported	—	Q2 FY26 10-QJun 30, 2026
Itron	840	599	102*	43.9M	—	Q3 FY26 10-QSep 30, 2026
Revvity	1,023	730	192*	111.6M	—	Q2 FY26 10-QJul 5, 2026
Ralliant	271	568	106*	110.6M	—	Q2 FY26 10-QJul 3, 2026
Vontier	266	757	116*	135.2M	—	Q2 FY26 10-QJul 3, 2026
Bruker	185	839	(77)*	152.4M	2.4 quarters	Q2 FY26 10-QJun 30, 2026
Trimble	214	972	240*	233.2M	—	Q2 FY26 10-QJul 3, 2026
Sensata Technologies Holding	553	1,004	225*	145.6M	—	Q3 FY26 10-QSep 30, 2026
Mettler Toledo International	51	1,027	310*	20.0M	—	Q2 FY24 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.